Ankilozan Spondilitli Bir Olguda Etanerceptile İlişkili Verruca Vulgaris Alevlenmesi

I have read with great interest the manuscript titled “Cervix Cancer in a Patient with Ankylosing Spondylitis Using Etanercept: A Case Report” authored by Doruk et al. (1) and would like to share my experience with regard to a patient develops severe exacerbation of verruca vulgaris under treatment with etanercept. Verruca vulgaris (common wart) is an infectious disease caused by human papilloma virus (HPV) that is an important risk factor for cervix cancer (2).A 20yearold male patient was diagnosed with ankylosing spondylitis (AS) resistant to conventional therapy, three years ago. Treatment with subcutaneous etanercept (50 mg/week) was initiated. The patient responded well to etanercept and this treatment was continued. When the patient last came to the outpatient clinic, he complained that he had numerous warts on his hands. The patient reported that, there was only one and small wart on his right hand before etanercept treatment. He had taken etanercept treatment for three years. During this period, the size and number of warts had increased. In the laboratory analyzes, routine biochemical, hematological, and urine tests were found to be within normal limits. Serology for HIV, hepatitis B and C viruses were negative. The chest Xray was evaluated as normal. The patient referred to a dermatologist for the evaluation of these skin lesions. He was diagnosed with verruca vulgaris, and etanercept treatment was discontinued